{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:43Z","timestamp":1787840383886,"version":"build-2784847793"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chemotherapy in an integral part of cancer treatment, either administered alone or in combination with radiation. However, the cost of these drugs is often prohibitively high for most patients. To address this issue, the Government of India has established Jan Aushadhi (JAS) stores across the country, where affordable generic medicines are available. In the current study, we performed a cost minimization analysis comparing JAS drugs with branded chemotherapeutic drugs used in various cancer treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study was to conduct a cost-minimization analysis by comparing the costs of different regimens when using JAS drugs, the most expensive branded drugs, and the least expensive branded drugs in the treatment of cancer in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The study focused on conducting a cost minimization analysis of various chemotherapy drugs used in the treatment of different cancers, considering the availability of anticancer drugs at JAS stores. The costs for different chemotherapy regimens, including both anticancer and supportive drugs, were calculated for single and complete cycles. The costs of the most expensive and least expensive branded drugs were noted from the Current Index of Medical Stores. The cost difference (CD) was calculated by subtracting the cost of the cheaper drug from that of the costliest brand. The cost ratio (CR) and the percentage of cost variation (PCV) were calculated for India-specific conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study analyzed the CD for various regimens using JAS drugs for chemotherapy treatment of breast, esophagus, rectal, colon, stomach, prostate, ovary, endometrial, cervical, head and neck, lung, multiple myeloma, testicular, and lymphoma cancers. It also considered chemoirradiation regimens for brain, head and neck, anorectal, esophageal, and uterine cervical cancers. Significant CDs were observed when both anticancer and supportive drugs were obtained from JAS stores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>To the best of the authors\u2019 knowledge, this is the first study to consider the CD, CR, and PCV for various regimens using JAS drugs, as well as the costliest and cheapest branded drugs in standard cancer treatment regimens. The results of this study are expected to assist healthcare professionals and pharmacists in understanding the cost-saving benefits of substituting expensive branded drugs with more affordable chemotherapeutic drugs for the treatment of cancer. This substitution can provide financial benefit for socioeconomically marginalized population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2387_22","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:02:05Z","timestamp":1728295325000},"page":"1472-1485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cost analysis of anticancer chemotherapy and chemoirradiation regimens considering the drugs marketed through Jan Aushadhi (People\u2019s Medicine) stores and their branded counterparts: First cost comparison study"],"prefix":"10.4103","volume":"20","author":[{"given":"Abhishek","family":"Krishna","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mysore Medical College and Research Institute, Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mysore Medical College and Research Institute, Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy L.","family":"Palatty","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanya","family":"Sacheendran","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Jayachandran","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"George","sequence":"additional","affiliation":[{"name":"Internal Medicine, Coney Island Hospital, Brooklyn, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Baliga","sequence":"additional","affiliation":[{"name":"Research Department, Mangalore Institute of Oncology, Mangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"R2-20241226","doi-asserted-by":"crossref","first-page":"162","DOI":"10.31768\/2312-8852.2015.37(3):162-172","article-title":"Hormonal impact on tumor growth and progression","volume":"37","author":"Reznikov","year":"2015","journal-title":"Exp Oncol"},{"key":"R3-20241226","first-page":"1","article-title":"History of the growing burden of cancer in India: From antiquity to the 21st century","volume":"5","author":"Smith","year":"2019","journal-title":"J Glob Oncol"},{"key":"R4-20241226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics. 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R5-20241226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canep.2018.12.003","article-title":"Transition of cancer in populations in India","volume":"58","author":"Mathew","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R6-20241226","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/GO.20.00122","article-title":"Cancer statistics, 2020: Report from national cancer registry programme, India","volume":"6","author":"Mathur","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"R7-20241226","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ajco.12661","article-title":"Epidemiology of breast cancer in Indian women","volume":"13","author":"Malvia","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R8-20241226","doi-asserted-by":"crossref","first-page":"e0193320","DOI":"10.1371\/journal.pone.0193320","article-title":"Economic burden of cancer in India: Evidence from cross-sectional nationally representative household survey, 2014","volume":"13","author":"Rajpal","year":"2018","journal-title":"PLoS One"},{"key":"R9-20241226","doi-asserted-by":"crossref","first-page":"71548","DOI":"10.18632\/oncotarget.17742","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"key":"R10-20241226","first-page":"FC17","article-title":"Variation of cost among anti-cancer drugs available in Indian market","volume":"10","author":"Kolasani","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R11-20241226","doi-asserted-by":"crossref","first-page":"642","DOI":"10.18203\/2319-2003.ijbcp20191010","article-title":"Price variation in different brands of anticancer drugs available in Indian pharmaceutical market: A cost analysis study","volume":"8","author":"Adwal","year":"2019","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R12-20241226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.15171\/ijhpm.2017.02","article-title":"A cost analysis of the Jan Aushadhi scheme in India","volume":"6","author":"Mukherjee","year":"2017","journal-title":"Int J Health Policy Manag"},{"key":"R13-20241226","first-page":"e19231","article-title":"Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: The first cost comparison study","volume":"13","author":"George","year":"2021","journal-title":"Cureus"},{"key":"R15-20241226","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14737167.2019.1637735","article-title":"Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer-A deep insight from India","volume":"20","author":"Kashyap","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R17-20241226","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.1998.16.11.3714","article-title":"Cancer chemotherapy and body surface area","volume":"16","author":"Pinkel","year":"1998","journal-title":"J Clin Oncol"},{"key":"R19-20241226","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5455\/njppp.2015.5.170720141","article-title":"A study on the knowledge, attitude, and practice of generic medicines among the doctors in a tertiary care teaching hospital in South India","volume":"5","author":"Gupta","year":"2015","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"R20-20241226","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"R21-20241226","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","article-title":"Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish lung cancer study group","volume":"23","author":"Sederholm","year":"2005","journal-title":"J Clin Oncol"},{"key":"R22-20241226","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1759-7714.12058","article-title":"Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer","volume":"5","author":"Zhang","year":"2014","journal-title":"Thorac Cancer"},{"key":"R23-20241226","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: Final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"key":"R24-20241226","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"Treatment of non-Hodgkin's lymphoma","volume":"328","author":"Armitage","year":"1993","journal-title":"N Engl J Med"},{"key":"R25-20241226","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"R26-20241226","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R27-20241226","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"R28-20241226","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/bloodadvances.2021004194","article-title":"Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs","volume":"5","author":"Er\u00e7al\u0131\u015fkan","year":"2021","journal-title":"Blood Adv"},{"key":"R29-20241226","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: Survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R30-20241226","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-020-04289-8","article-title":"Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: Sharing experience of a hemato-oncology center from eastern India","volume":"100","author":"Phukan","year":"2021","journal-title":"Ann Hematol"},{"key":"R32-20241226","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-015-0415-3","article-title":"What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs","volume":"13","author":"Dunne","year":"2015","journal-title":"BMC Med"},{"key":"R33-20241226","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/crst.crst_66_21","article-title":"Drug pricing: A major barrier to access to cancer care in India","volume":"4","author":"Radhakrishnan","year":"2021","journal-title":"Cancer Res Stat Treat"},{"key":"R34-20241226","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/jpgm.JPGM_420_18","article-title":"Generic drugs-The Indian scenario","volume":"65","author":"Joshi","year":"2019","journal-title":"J Postgrad Med"},{"key":"R35-20241226","first-page":"204","article-title":"Jan Aushadhi stores in India and quality of medicines therein","volume":"3","author":"Singhal","year":"2011","journal-title":"Int J Pharm Pharm Sci"},{"key":"R36-20241226","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5530\/ijpi.2020.3.47","article-title":"A review on regulatory requirements to prevent counterfeit drugs in India","volume":"10","author":"Mourya","year":"2020","journal-title":"Int J Pharm Investigation"},{"key":"R37-20241226","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11277-020-07041-7","article-title":"Securing e-health networks from counterfeit medicine penetration using blockchain","volume":"117","author":"Pandey","year":"2021","journal-title":"Wirel Pers Commun"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2387_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:49Z","timestamp":1787836909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2387_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2387_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2022-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}